WCN26-4164 ASSOCIATIONS BETWEEN USE OF SGLT2 INHIBITOR AND TUBULAR GLYCOGEN VACUOLIZATION (ARMANNI-EBSTEIN LESION) IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH/ WITHOUT DIABETES

Read full text Summarise with VIRAT
Authors: Megumi Takahashi, Yumi Ito, Ryohei Kaseda, Hideyuki Kabasawa, Michihiro Hosojima, Suguru Yamamoto
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Armanni–Ebstein lesion (AEL) is characterized by the vacuolization of tubular epithelial cells in the outer stripe of the outer medulla due to abnormal cytoplasmic glycogen accumulation. It typically occurs in patients with poorly controlled diabetes and is associated with hyperglycemia and glycosuria. Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) lowers blood glucose levels by blocking glucose reabsorption in the S1–S2 segments of the proximal tubules, thereby increasing urinary glucose excretion.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105943–105943
Publication date
25 March 2026
Language
EN